Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Eleda Infra Services Group (“Eleda”) on the acquisition of Dalarnas Infraentreprenad AB
Mandate

Vinge has advised Eleda Infra Services Group (“Eleda”) on the acquisition of Dalarnas Infraentreprenad AB

March 28, 2021 Employment and Benefits Corporate Tax M&A

Dalarnas Infraentreprenad AB is a company focused on performing contracts for railways and roads in Sweden.

The company is especially focused on building fences and noise barriers for railways in Sweden with the Swedish Transport Administration (Sw. Trafikverket) as the largest customer. The company’s management team will continue in their respective operational management roles and become shareholders of the Eleda group.

Vinge’s team consisted primarily of partner Christina Kokko and associates Michaela Cronemyr and Hanna Risberg (M&A), Ebba Svenburg (Employment) and Frida Ställborn (Real Property & Environment).

 

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026